OptimizeRx (OPRX) Projected to Post Earnings on Tuesday

OptimizeRx (NASDAQ:OPRX) is expected to be issuing its Q1 2026 results after the market closes on Tuesday, May 12th. Analysts expect OptimizeRx to post earnings of $0.01 per share and revenue of $18.3530 million for the quarter. Individuals can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Tuesday, May 12, 2026 at 4:30 PM ET.

OptimizeRx (NASDAQ:OPRX) last released its earnings results on Saturday, January 31st. The company reported $0.51 earnings per share (EPS) for the quarter. OptimizeRx had a return on equity of 10.61% and a net margin of 4.69%. On average, analysts expect OptimizeRx to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

OptimizeRx Stock Performance

Shares of OptimizeRx stock traded down $0.18 during trading hours on Tuesday, hitting $6.59. 167,833 shares of the company were exchanged, compared to its average volume of 439,579. The company has a current ratio of 3.04, a quick ratio of 3.04 and a debt-to-equity ratio of 0.17. The business has a 50-day moving average of $6.74 and a 200-day moving average of $11.50. OptimizeRx has a 1 year low of $5.54 and a 1 year high of $22.25. The stock has a market capitalization of $123.61 million, a price-to-earnings ratio of 25.32 and a beta of 1.19.

OptimizeRx declared that its Board of Directors has initiated a stock repurchase plan on Thursday, March 5th that permits the company to repurchase $10.00 million in outstanding shares. This repurchase authorization permits the company to repurchase up to 6.8% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board believes its stock is undervalued.

Institutional Investors Weigh In On OptimizeRx

Institutional investors and hedge funds have recently modified their holdings of the company. Quantbot Technologies LP purchased a new position in OptimizeRx in the 2nd quarter valued at approximately $44,000. BNP Paribas Financial Markets raised its stake in shares of OptimizeRx by 119.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 4,074 shares of the company’s stock worth $55,000 after buying an additional 2,215 shares during the last quarter. Worth Venture Partners LLC acquired a new position in shares of OptimizeRx during the 3rd quarter worth $220,000. ExodusPoint Capital Management LP purchased a new stake in shares of OptimizeRx in the 4th quarter worth about $150,000. Finally, Campbell & CO Investment Adviser LLC acquired a new stake in OptimizeRx in the 4th quarter valued at about $158,000. Institutional investors and hedge funds own 76.47% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on OPRX. Stifel Nicolaus reduced their target price on shares of OptimizeRx from $21.00 to $17.00 and set a “buy” rating for the company in a research note on Friday, March 6th. B. Riley Financial reissued a “buy” rating and set a $11.00 price target (down from $28.00) on shares of OptimizeRx in a report on Friday, March 6th. Stephens lowered their price objective on OptimizeRx from $17.00 to $10.00 and set an “equal weight” rating on the stock in a report on Friday, March 6th. Roth Mkm reduced their price target on OptimizeRx from $32.00 to $18.00 and set a “buy” rating for the company in a report on Friday, March 6th. Finally, Zacks Research upgraded OptimizeRx from a “hold” rating to a “strong-buy” rating in a research note on Friday, March 13th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, OptimizeRx currently has an average rating of “Moderate Buy” and a consensus target price of $17.57.

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.